Certainly encouraging to hear from the CML community.
Target population for T315I patients is small (but growing), and don't forget, CXS has been granted Orphan Drug Status. And T315I is only the first proposed indication for Omapro. CXS will also apply for approval in patients who have failed 2nd line TKI's and who do not have the T315I mutation.
petition from t315i patients on the web, page-2
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
